# The tesamorelin cognition trial

> Philadelphia Anti Aging examines a cognition trial — Philadelphia Anti Aging examines the tesamorelin trial in 152 older adults: cognition, IGF-1, body fat and the question of everyday mental life.

Cognition measured in people gives this paper its subject. The hormone result is only one item on the agenda.

## The study population

The [controlled trial enrolled 152 older adults, including 66 with mild cognitive impairment](https://pubmed.ncbi.nlm.nih.gov/22869065/). It was randomized, double-blind and placebo-controlled, and the intervention lasted 20 weeks. The GHRH analogue was tesamorelin.

That last name matters here. The paper’s title says “growth hormone-releasing hormone,” which can sound broader than the actual intervention. Credit ought to stay with the compound and population that produced the finding. This is human cognition evidence for a particular GHRH analogue, rather than an invitation to substitute another one.

![An adult volunteer arranges geometric pieces while another adult observes at a desk](images/cognitive-session.webp)

*An imagined cognitive-testing session. The people and materials are illustrative, with no claim to reproduce the trial’s test battery.*

## The cognitive and metabolic outcomes

The trial reported a [favorable effect on cognition, including executive function, alongside a 117% increase in IGF-1 within the physiologic range and a 7.4% reduction in percent body fat](https://pubmed.ncbi.nlm.nih.gov/22869065/). Adverse events were described as mild.

For me, cognition leads the discussion. The large IGF-1 change is easy to make into a headline, yet the ability being investigated gives the experiment its purpose. These outcomes were reported together; they still require separate judgments about their value.

The body-fat figure describes a reduction in percent body fat. It does not report a 7.4% loss of total body weight. Preserving that distinction prevents an unrelated weight-loss claim from slipping into a discussion of cognition.

## Everyday cognitive activities

I picture a useful cognitive result carrying into an argument, a decision, an engrossing conversation. Those are my hopes for an anti-aging intervention, extending beyond the outcomes reported in this paper. The [reported finding concerns cognition over the trial’s 20 weeks](https://pubmed.ncbi.nlm.nih.gov/22869065/).

The next account capable of persuading me would connect measured improvement with activities people value and show how long it lasts. Its metabolic consequences would need to sit close enough to the cognitive findings for a fair judgment of the trade. A favorable test result can justify that interest without settling the whole question.

## The congenital-deficiency comparison

A [brain-imaging comparison in adults with congenital untreated GH deficiency](https://pubmed.ncbi.nlm.nih.gov/38627331/) complicates any claim that an active GH axis is essential to avoiding accelerated brain aging. It studied a very different population and asked a structural question.

Forcing a verdict for or against all GHRH research would ask these studies to settle a question neither tested. Their disagreement is useful precisely because they put different propositions on the table. The [brain-age page](/brain-age) follows that narrower dissent; the [metabolic account](/metabolic-account) considers findings elsewhere in the body.

---

Philadelphia Anti Aging brings my objections and enthusiasms to published research on the aging mind; it runs no business and gives no medical advice.